Overview

Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis

Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety, tolerability, and efficacy of Alefacept in patient with moderate to severe atopic dermatitis who could not be adequately controlled with topical therapies.
Phase:
Phase 4
Details
Lead Sponsor:
Rush University Medical Center
Collaborator:
Astellas Pharma US, Inc.
Treatments:
Alefacept